Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence...
Roche stock was unmoved early Thursday after the drugmaker matched sales expectations despite light pharma sales.
Roche reiterated its full-year guidance and said it is prepared to launch its giredestrant breast-cancer pill later this year.
Roche third quarter sales slightly beat expectations with growth across divisions
Roche said on Wednesday late-stage trial data showed its experimental drug fenebrutinib reduced markers of chronic brain inflammation and delivered broader disease control than comparator treatments in patients with relapsing and primary progressive multiple sclerosis (MS).
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
Roche said on Monday it will present new late-stage trial results at the ESMO 2026 cancer meeting in Madrid, including data showing its lung cancer drug divarasib worked better than current KRAS G12C treatments.